Interleukin 12-activated lymphocytes influence tumor genetic programs

Cancer Research

Volumn 61, Issue 8, 2001, Pages 3518-3523

  Cavallo, Federica ^a   Quaglino, Elena ^a   Cifaldi, Loredana ^a   Di Carlo, Emma ^b   André, Alessandra ^c   Bernabei, Paola ^a   Musiani, Piero ^b   Forni, Guido ^a   Calogero, Raffaele A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CD28 ANTIGEN; CD3 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 12; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION TERMINATION FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENETICS; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERFERON TYPE II; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0035870277     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. The hallmarks of cancer
2. Tumor immunology: The glass is half full
3. Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice
4. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts
5. Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines
6. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
7. Differential tumor surveillance by natural killer (NK) and NKT cells
8. The intriguing role of polymorphonuclear neutrophils in antitumor reactions
9. Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy
10. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
11. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12
12. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene
13. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
14. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
15. TS/A: A new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma
16. Inhibition of interferon-γ may suppress allograft reactivity by T lymphocytes in vitro and in vivo
17. Detection of intracellular phosphorylated STAT-1 by flow cytometry
18. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
19. Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor
20. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma
21. CD14
22. Recombinant IL-12 administration induces tumor regression in association with IFNγ production
23. Evidence for a precursor of the high-affinity metastasis-associated murine laminin receptor
24. Molecular cloning and expression of neuroleukin, a neurotrophic factor for spinal and sensory neurons
25. The role of Mig, the monokine induced by interferon-γ, and IP-10, the intefferon-γ-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative diseases
26. Tumor angiogenesis: Past, present and the near future
27. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
28. The role of CXC chemokines in the regulation of angiogenensis
29. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
30. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
31. Molecular portraits of human breast tumours